CRP and non-small cell lung carcinoma: The emerging CRP flare kinetic was defined as an early doubling of baseline CRP followed by a drop below baseline by Fukuda et al. (2021), and its predictive value has just recently been validated in a Phase III pivotal clinical trial for non-small cell lung cancer [12].